Connect your AI

Mirum Pharmaceuticals, Inc. MIRM Price / book

Price / book at other companies

Gilead SciencesGILD

7.4×+0.1×

Rhythm Pharmaceuticals, Inc.RYTM

48.3×-128×

Arrowhead ResearchARWR

14.3×+11.7×

LQD

Liquidia CorporationLQDA

30.6×+5.3×

AlkermesALKS

3.4×-0.2×

Ionis PharmaceuticalsIONS

25.2×+15.2×

Other financials

Income statement

Revenue$159.9M+43.3%

Operating income-$789.5M-5,100%

Net income-$790.2M-5,284%

EPS (diluted)-$13.43-4,377%

Balance sheet

Cash & equivalents$261.5M+43.5%

Total debt$13.5M+56.4%

Total equity$242.5M+4.0%

Total assets$890.9M+29.1%

Cash flow

Operating cash flow-$228.8M-11,566%

CapEx$664.0K+1,520%

Free cash flow-$229.4M-11,360%

Valuation

Market cap$6.53B+152%

Enterprise value$6.28B+162%

P/S11.5×+4.6×

Profitability

Operating margin-139.8%-168pp

Net margin-140.2%-169pp

FCF margin-30.3%—

Returns & leverage

Return on equity-335.8%-377pp

Debt / equity0.1×0.0×

Current ratio2.1×-1.1×

Where this comes from

Calculated from Mirum Pharmaceuticals, Inc.’s reported figures.

market cap/total stockholders equity=23×

Based on the most recent quarter.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s price / book?: Mirum Pharmaceuticals, Inc. (MIRM) reported price / book of 23× in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s price / book changed year-over-year?: Mirum Pharmaceuticals, Inc.'s price / book increased by 142.8% year-over-year, from 9.5× to 23×.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s price / book?: Over 5 years (2020 to 2025), Mirum Pharmaceuticals, Inc.'s price / book has grown at a 33.1% compound annual growth rate (CAGR), from 3.1× to 13×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.